Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence
Seasonal influenza is a very common disease. Yearly vaccination of at-risk population groups is a well-recognized cost-effective/cost-saving preventive measure. It is, however, unclear which available alternative has the most favorable economic profile. Some available options are: trivalent (TIV) an...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis Group
2019-05-01
|
| Saila: | Human Vaccines & Immunotherapeutics |
| Gaiak: | |
| Sarrera elektronikoa: | http://dx.doi.org/10.1080/21645515.2019.1578597 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|